Cargando…
A cell-permeable peptide-based PROTAC against the oncoprotein CREPT proficiently inhibits pancreatic cancer
Cancers remain a threat to human health due to the lack of effective therapeutic strategies. Great effort has been devoted to the discovery of drug targets to treat cancers, but novel oncoproteins still need to be unveiled for efficient therapy. Methods: We show that CREPT is highly expressed in pan...
Autores principales: | Ma, Danhui, Zou, Yutian, Chu, Yunxiang, Liu, Zhengsheng, Liu, Gaochao, Chu, Jun, Li, Mengdi, Wang, Jiayu, Sun, Shi-yong, Chang, Zhijie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069095/ https://www.ncbi.nlm.nih.gov/pubmed/32206117 http://dx.doi.org/10.7150/thno.41677 |
Ejemplares similares
-
The PROTAC technology in drug development
por: Zou, Yutian, et al.
Publicado: (2019) -
CREPT is required for murine stem cell maintenance during intestinal regeneration
por: Yang, Liu, et al.
Publicado: (2021) -
CREPT Disarms the Inhibitory Activity of HDAC1 on Oncogene Expression to Promote Tumorigenesis
por: Cao, Yajun, et al.
Publicado: (2022) -
CREPT/RPRD1B associates with Aurora B to regulate Cyclin B1 expression for accelerating the G2/M transition in gastric cancer
por: Ding, Lidan, et al.
Publicado: (2018) -
PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
por: Kelm, Jeremy M., et al.
Publicado: (2023)